Trial Profile
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2020
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Pityriasis rubra pilaris
- Focus Therapeutic Use
- 15 Apr 2020 Results published in the JAMA Dermatology
- 03 Mar 2020 Status changed from active, no longer recruiting to completed.
- 10 Dec 2019 Planned End Date changed from 30 Nov 2019 to 6 Jan 2020.